Methods for treating immune-mediated dengue fever infections and antibody-dependent enhancement of dengue fever infections, including dengue hemorrhagic fever and dengue shock syndrome
AssigneeTrinity Therapeutics, Inc.
InventorNeil M. Bodie
Life of this patent
Estimating the term…
Abstract
Polypeptides and other compounds that can bind specifically to the CH2-CH3 cleft of an immunoglobulin molecule, and methods for using such polypeptides and compounds to inhibit Fc-mediated immune complex formation in viral infection. For example, polypeptides and other compounds can be used to inhibit binding of DF-associated, immune-complexed IgG anti-DF viron(s) or DV viral antigens to FγR, ADE of DF/DHF/DSS infections by inhibition of DF viral antigen binding to immune complexed IgG, FγR and immune complexed IgG mC1q (membrane C1q) or soluble C1q binding.
Claims27
A method for inhibiting immune complex formation in a subject, said method comprising administering to said subject a composition comprising a purified polypeptide, said polypeptide comprising the amino acid sequence (Xaa1)m-Cys-Ala-Xaa2-His-Leu-Gly-Glu-Leu-Val-Trp-Cys-Thr-(Xaa3)n (SEQ ID NO:53), wherein Xaa1 is any amino acid, Xaa2 is Trp, Tyr or Phe, 5-Hydroxytrphophan (5-HTP), 5-hydroxytryptamine (5-HT), or another amino acid derivative, Xaa3 is any amino acid, and m and n independently are 0, 1, 2, 3, 4, or 5, and wherein said immune complex formation is associated with a viral infection.
Dependencies are inferred from the claim text.